Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Patella, Vincenzo
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma ().	Completed	3	836	Europe, RoW	CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant	Chiesi Farmaceutici S.p.A.	Asthma	11/24	02/25
RAPID, NCT04287621: Registry of Asthma Patients Initiating DUPIXENT®	Active, not recruiting	N/A	718	Europe, Canada, Japan, US	DUPIXENT®, dupilumab, REGN668, SAR231893	Regeneron Pharmaceuticals, Sanofi	Asthma	07/26	07/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Patella, Vincenzo
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma ().	Completed	3	836	Europe, RoW	CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant	Chiesi Farmaceutici S.p.A.	Asthma	11/24	02/25
RAPID, NCT04287621: Registry of Asthma Patients Initiating DUPIXENT®	Active, not recruiting	N/A	718	Europe, Canada, Japan, US	DUPIXENT®, dupilumab, REGN668, SAR231893	Regeneron Pharmaceuticals, Sanofi	Asthma	07/26	07/26